Key result
In normal canines, cenderitide increased urinary cGMP excretion, natriuresis, and glomerular filtration rate, whereas CNP did not, demonstrating its renal-enhancing actions.
Cenderitide acts as a dual pGC-A and pGC-B activator, enhancing renal function and cGMP production in normal canines, suggesting potential utility in cardiorenal disease.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for dual pGC-A/B agonism in cardiorenal disease; extends canine data but leaves human translation open.
Lee et al. (2015) studied Normal canines (in vivo/ex vivo) and HEK 293 cells (in vitro). Cenderitide vs. CNP (C-type natriuretic peptide) and CNP-based variants was evaluated on Renal function and cyclic guanosine monophosphate (cGMP) production. In normal canines, cenderitide increased urinary cGMP excretion, natriuresis, and glomerular filtration rate, whereas CNP did not, demonstrating its renal-enhancing actions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: